

Gene Therapy – Transforming The Clinical Outlook For Neuromuscular Diseases

Friday 21 May 2021, 17:15 – 18:00 CEST

Dear Colleagues,

Join us on **Friday 21 May 2021, 17:15–18:00 CEST** for this Novartis Gene Therapies-sponsored virtual educational symposium entitled: **‘Gene Therapy – Transforming the Clinical Outlook for Neuromuscular Diseases’** where you will have the opportunity to learn about the emerging role of gene therapy (GT) in the challenging therapeutic landscape for neuromuscular diseases (NMD). Our faculty of experts will share their experiences to provide insight into the latest advances in gene therapy research and address the importance of emergent modes of treatment for NMD and the role of newborn screening for optimizing outcomes for affected individuals. To finish the program, our experts will deliver a panel discussion before closing with a Q&A session.

Agenda




17:15–17:30 – Welcome, introduction & challenges of early treatment in neuromuscular diseases

Professor Laurent Servais, *Professor of Paediatric Neuromuscular Diseases, MDUK Oxford Neuromuscular Centre, UK*



17:30–17:45 – Potential of gene therapy for neuromuscular diseases

Professor Janbernd Kirschner, *Medical Director, Department of Neuropediatrics, University Hospital Bonn, Germany*



17:45–17:55 – Panel discussion - Capturing the clinical perspective on gene therapy

Dr Sandra Reyna (moderator), **Professor Servais**, **Professor Kirschner**, *Vice President, Global Medical Affairs, Novartis Gene Therapies, United States*

17:55–18:00 – Q&A and Close

Dr Sandra Reyna

We look forward to welcoming you for what promises to be an informative and engaging virtual event.